Latest From Retrophin Inc.
A Phase III trial design change could result in quicker patient access for Calliditas’s product candidate for Berger’s disease, and boost the growth potential for the Swedish biotech.
Fosmetpantotenate missed all endpoints in a Phase III trial, so Retrophin will shelve the candidate for the rare disease PKAN. Now, the biotech turns focus to Phase III sparsentan in a pair of indications.
Building on research by Dana-Farber professor Wayne Marasco, the partners are backing a bispecific approach to CAR-Ts in solid tumors. Seelos licenses a Parkinson’s gene therapy candidate from Duke.
User fee goal date calendar for June includes AMAG’s female sexual dysfunction drug Vyleesi, new indications for Sanofi/Regeneron’s Dupixent in rhinosinusitis and Merck’s Zerbaxa in nosocomial pneumonia.
- Large Molecule
- Drug Delivery
- Therapeutic Areas
- Metabolic Disorders
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Renal System
- Retrophin LLC
- North America
- Parent & Subsidiaries
- Retrophin Inc.
- Senior Management
Eric Dube, PhD, Pres. & CEO
Laura M Clague, CFO
Noah L Rosenberg, MD, CMO
Peter Heerma, Chief Commercial Officer
- Contact Info
Phone: (760) 260-8600
3721 Valley Centre Dr., Ste. 200
San Diego, CA 92130
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.